Journals / Medical Network Klinik Bilimler ve Doktor / 2002 / Cilt: 8 - Sayı: 3

The place of oral methylprednisolone in the treatment of refractory hyperemesis gravidarum

Refrakter hiperemezis gravidarum'un tedavisinde oral metilprednisolon'un yeri

Pages
367–370
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

CONCLUSION: A short course of oral methylprednisolone appears to be a reasonable therapeutic alterantive for intractable hyperemesis gravidarum.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:OBJECTIVE: Our purpose was to evaluate the effect of oral methylprednisolone on the course of refractory hyperemesis gravidarum.
📊
Key Findings & Data:MATERIAL AND METHODS: Patients with the diagnosis' of hyperemesis gravidarum who were admitted to SSK Aegean Maternity Hospital in between September 1998 and June 2000 and refractory to convansional treatment modalities were included into the study.
💡
Conclusion & Impact:CONCLUSION: A short course of oral methylprednisolone appears to be a reasonable therapeutic alterantive for intractable hyperemesis gravidarum.
🔬Design:Research Article
📍Scope:2000 Verileri
⚙️Variables:Hiperemezis gravidarum · Metilprednizolon · Gebelik komplikasyonları

Abstract

OBJECTIVE: Our purpose was to evaluate the effect of oral methylprednisolone on the course of refractory hyperemesis gravidarum. MATERIAL AND METHODS: Patients with the diagnosis' of hyperemesis gravidarum who were admitted to SSK Aegean Maternity Hospital in between September 1998 and June 2000 and refractory to convansional treatment modalities were included into the study. Patients with multiple gestations, fetal or placental anomalies and suspected or proven medical or surgical diseases that could have explained the vomiting were not offered this treatment. 30 patients with intractable hyperemesis gravidarum were admitted to the hospital. 48 mg oral methylprednisolone per day for three days were given to these thirty patients with gestations in between 8 and 20 weeks. The dosage was tapered over 2 weeks. The treatment protocol was again given to patients who were refractory to this treatment or to patients with recurrence of vomiting symptoms at the end of these two weeks. And the treatment was continued for not over one month. RESULTS: Twenty-five of thirty patients (83.3%) were free of vomiting and were able to tolerate a regular diet within 3 days of starting methylprednisolone therapy. Fourteen of twenty-five patients (56%) didnot have recurrence of vomiting for the remainder of the pregnancy. Recurrence of symptoms was observed in nine patients (36%) after the therapy or during the tapering of the dosage period. All of these nine patients responded to prolongation of the therapy. Two patients (8%) responded to the therapy at 28th-29th days of the prolonged therapy and these two patients were also free of symptoms for the rest of the pregnancy. From the remaining five of thirty patients; one developed intolerance to methylprednisolone, three patients developed recurrence of the symptoms during the tapering phase of prolonged therapy and the last patient didnot respond to any of the therapies and total parenteral nutrition was begun because of generalized depressed condition. CONCLUSION: A short course of oral methylprednisolone appears to be a reasonable therapeutic alterantive for intractable hyperemesis gravidarum.

Özet

AMAÇ: Konvansiyonel tedaviye dirençli gebelik kusmalarının sağaltımında oral Metilprednisolon'un etkisini inceledik. GEREÇ VE YÖNTEM: SSK Ege Doğumevi'nde Eylül 1998- Haziran 2000 tarihleri arasında hiperemezis gravidarum tanısı konup alışılagelmiş tedavilere yanıt vermeyen gebeler çalışmaya alındı. Çoğul gebelik, fetal veya plasental anomalili, şüpheli veya kanıtlanmış hastalığı olan gebeler çalışma dışı bırakıldı. 8 ile 20 hafta arasında refrakter hiperemezis gravidarum tanısı alan 30 hastaya 3 gün boyunca günde 48 mg oral metilprednisolon verildi. Doz iki hafta boyunca azaltılarak kesildi. İki hafta sonunda tedaviye yanıt vermeyen veya yakınmaları yeniden başlayan gebelere aynı dozda tedavi tekrar başlandı ve 1 aylık süreden uzun olmamak üzere tedaviye devam edildi. BULGULAR: Otuz hastanın yirmibeşinde (%83.3) bulantı ve kusma şikayetleri kesildi, ve 3 gün içinde düzenli olarak dietlerini almaya başladılar. Yirmibeş hastanın ondördünde (%56) gebelikleri boyunca herhangi bir şikayet tespit edilmedi. Dokuz hastada (%36) tedavi sonrası veya doz azaltımı sırasında şikayetler tekrarladı. Bu hastaların tamamı tedavinin uzatılmasına cevap verdi. İki hasta (%8) ise ancak uzatılmış tedavinin 28-29.'uncu günü tedaviye yanıt vermeye başladı ve bunlarında gebelikleri süresince şikayetleri tekrarlamadı. Geri kalan beş hastanın birinde metilprednisolon'a intolerans gelişirken, üçünde uzatılmış tedavinin doz azaltımı sırasında rekürrens tespit edildi, kalan diğer hastada ise herhangi bir şekilde tedaviye yanıt alınamayarak, genel durum bozukluğu sebebiyle total parenteral nütrisyon uygulandı. SONUÇ: Kısa süreli oral Metilprednisolon tedavisinin refrakter hiperemezis gravidarumun sağaltımında anlamlı bir alternatif olduğu düşünülmektedir.

🔖

Cite This Article

SANCI, M., İNAL, M. M., GÜLER, A., ÖZGÜDER, T., ARICI, A., İSPAHİ, Ç., TINAR, Ş. (2002). The place of oral methylprednisolone in the treatment of refractory hyperemesis gravidarum. Medical Network Klinik Bilimler ve Doktor, Cilt: 8 - Sayı: 3, 367–370. https://ajindex.com/articles/279184

References (14)

  1. Gadsby R, Barnie-Adhead AM, Jagget C. A prospective study of nausea and vomiting during pregnancy. Br J Gen Pract 1993; 43:245-8.
  2. Fairweather DVI, Loraine JA. Nausea and vomiting in pregnancy. Am J obstet Gynecol 1968; 102:135-75.
  3. Wood P, Murray A, Sinha B, Godley M, Goldsmith HJ. Wernicke's encephalopathy induced by hyperemesis gravidarum. Br J Obstet Gynecol 1983; 90:583-6.
  4. Ohloshi N, Ishii A, Shoji S. Wernicke's encephalopathy induced by hyperemesis gravidarum, associated with bilateral caudate lesion on computed tomography and magnetic resonance imaging. Eur Neurol 1994; 34:77-80.
  5. Woolford TJ, Birzgalis AR, Lundell C, Farrington WT. Vomiting in pregnancy resulting in esophageal perforation. J Laryngol Otol 1993; 107:1059-60.
  6. Chin RKH, Lao TT. Low birth weight and hyperemesis gravidarum. Eur J obstet Gynecol 1988; 28:179-83.
  7. Gross S, Librach C, Cecutti A. Maternal weight loss associated with hyperemesis gravidarum: a predictor of fetal outcome. Am J Obstet Gynecol 1989; 160:906-9.
  8. Stellato TA, Danziger LH, Pharm D, Burkons D. Fetal salvage with maternal total parenteral nutrition: the pregnant mother as her own control. J Parenteral Enteral Nutr 1988; 12:412-3. Nelson-Piercy C, de Swiet M. Corticosteroids for the treatment of hyperemesis gravidarum. Br J Obstet Gynecol 1994; 10:1013-5. Kemp WN. The treatment of early vomiting of pregnancy with suprarenal cortex: case reports. Endocrinology 1932; 16:434-6. Wells CN. Treatment of hypermemesis gravidarum with cortisone. Am J Obstet Gynecol 1953; 66:598-601.
  9. Ylikorkala O, Kauppila A, Ollanketo ML. Intramuscular ACTH or placebo in the treatment of hyperemesis gravidarum. Acta Obstet Gynecol Scand 1979; 58:453-5.
  10. Torre E, Ancona M, Capiluppi V, Pironti A, Benedetto C, Piccioni V. Psychosomatic assessment in patients with gravidic hyperemesis. Min Psichiatr 1992; 33:169-75.
  11. Kauppila A, Ylikorkala O, Jarvinen PA, Haapalahti J. The function of the anterior pituitary-adrenal cortex axis in hyperemesis gravidarum. Br J Obstet Gynecol 1976; 83:11-6.
  12. Chan GCP, Wilson AM, Wong CY, Daniel DG, Oladipo A, Nelson-Piercy C, et al. Complications of the use of corticosteroids for the treatment of hyperemesis gravidarum. Br J Obstet Gynecol 1995; 102:507-9.
  13. Magee LA, Redman CWG. An N-of-1 trial for treatment of hyperemesis gravidarum. Br J Obstet Gynecol 1996; 103:478-80.
  14. Beitins IZ, Bayard F, Ances IG, Kowaski A, Migem CJ. The transplacental pasage of prednisone and prednisolone in pregnancy near term. J Pediatr 1972; 81:93